These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
695 related articles for article (PubMed ID: 30499317)
1. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture. Medellin MR; Fujiwara T; Tillman RM; Jeys LM; Gregory J; Stevenson JD; Parry M; Abudu A Bone Joint J; 2018 Dec; 100-B(12):1626-1632. PubMed ID: 30499317 [TBL] [Abstract][Full Text] [Related]
2. Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone. Li D; Zhang J; Li Y; Xia J; Yang Y; Ren M; Liao Y; Yu S; Li X; Shen Y; Zhang Y; Yang Z World J Surg Oncol; 2016 Apr; 14():114. PubMed ID: 27094617 [TBL] [Abstract][Full Text] [Related]
3. Extended intralesional curettage preferred over resection-arthrodesis for giant cell tumour of the distal radius. Abuhejleh H; Wunder JS; Ferguson PC; Isler MH; Mottard S; Werier JA; Griffin AM; Turcotte RE Eur J Orthop Surg Traumatol; 2020 Jan; 30(1):11-17. PubMed ID: 31297594 [TBL] [Abstract][Full Text] [Related]
4. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence? Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015 [TBL] [Abstract][Full Text] [Related]
5. [Analysis of the risk factors for local recurrence of giant cell tumor of long bone]. Xu H; Niu X Zhonghua Zhong Liu Za Zhi; 2014 Jun; 36(6):465-8. PubMed ID: 25241792 [TBL] [Abstract][Full Text] [Related]
6. Does pathological fracture affect the rate of local recurrence in patients with a giant cell tumour of bone?: a meta-analysis. Salunke AA; Chen Y; Chen X; Tan JH; Singh G; Tai BC; Khin LW; Puhaindran ME Bone Joint J; 2015 Nov; 97-B(11):1566-71. PubMed ID: 26530662 [TBL] [Abstract][Full Text] [Related]
7. [Surgical treatment for long bone giant cell tumor of extremity with pathologic fracture]. Li X; Guo W; Yang Y; Wei R; DU ZY Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Oct; 45(5):745-51. PubMed ID: 24136271 [TBL] [Abstract][Full Text] [Related]
8. The role of Denosumab in joint preservation for patients with giant cell tumour of bone. Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180 [TBL] [Abstract][Full Text] [Related]
10. A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities. Campanacci L; Sambri A; Medellin MR; Cimatti P; Errani C; Donati DM Acta Orthop Traumatol Turc; 2019 Sep; 53(5):376-380. PubMed ID: 31253385 [TBL] [Abstract][Full Text] [Related]
11. [Surgical treatment of giant cell tumors with pathological fracture around the knee]. Liu WF; Yang FJ; Li Y; Li B; Hao L; Niu XH Zhonghua Wai Ke Za Zhi; 2018 Sep; 56(9):677-686. PubMed ID: 30157574 [No Abstract] [Full Text] [Related]
12. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience. Agarwal MG; Gundavda MK; Gupta R; Reddy R Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study. Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567 [TBL] [Abstract][Full Text] [Related]
14. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation. Tsukamoto S; Hindiskere S; Honoki K; Mavrogenis AF; Tanaka Y; Chinder PS; Donati DM; Errani C Int Orthop; 2023 Jan; 47(1):265-273. PubMed ID: 36282294 [TBL] [Abstract][Full Text] [Related]
15. Giant cell tumour of bone in the appendicular skeleton: an analysis of 276 cases. Xing R; Yang J; Kong Q; Tu C; Zhou Y; Duan H Acta Orthop Belg; 2013 Dec; 79(6):731-7. PubMed ID: 24563982 [TBL] [Abstract][Full Text] [Related]
16. Extended curettage versus en bloc resection for the treatment of grade 3 giant cell tumour of the knee with pathologic fracture: a retrospective study. Jamshidi K; Zandrahimi F; Haji Agha Bozorgi M; Arefpour AM; Bagherifard A; Al-Baseesee HH; Mirzaei A Int Orthop; 2021 Jan; 45(1):289-297. PubMed ID: 33001283 [TBL] [Abstract][Full Text] [Related]
17. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone. Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628 [TBL] [Abstract][Full Text] [Related]
18. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage. Errani C; Tsukamoto S; Leone G; Righi A; Akahane M; Tanaka Y; Donati DM J Bone Joint Surg Am; 2018 Mar; 100(6):496-504. PubMed ID: 29557866 [TBL] [Abstract][Full Text] [Related]
19. Giant cell tumor with pathologic fracture: should we curette or resect? van der Heijden L; Dijkstra PD; Campanacci DA; Gibbons CL; van de Sande MA Clin Orthop Relat Res; 2013 Mar; 471(3):820-9. PubMed ID: 22926445 [TBL] [Abstract][Full Text] [Related]
20. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. Rutkowski P; Gaston L; Borkowska A; Stacchiotti S; Gelderblom H; Baldi GG; Palmerini E; Casali P; Gronchi A; Parry M; Campanacci DA; Scoccianti G; Wagrodzki M; Ferrari S; Dijkstra S; Pieńkowski A; Grimer R Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]